INmune Pb Ratio vs Ptb Ratio Analysis

INMB Stock

USD 1.56 0.07 4.70%

INmune Bio financial indicator trend analysis is infinitely more than just investigating INmune Bio recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether INmune Bio is a good investment. Please check the relationship between INmune Bio Pb Ratio and its Ptb Ratio accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

Pb Ratio vs Ptb Ratio

Pb Ratio vs Ptb Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of INmune Bio Pb Ratio account and Ptb Ratio. At this time, the significance of the direction appears to have totally related.

The correlation between INmune Bio's Pb Ratio and Ptb Ratio is 1.0. Overlapping area represents the amount of variation of Pb Ratio that can explain the historical movement of Ptb Ratio in the same time period over historical financial statements of INmune Bio, assuming nothing else is changed. The correlation between historical values of INmune Bio's Pb Ratio and Ptb Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pb Ratio of INmune Bio are associated (or correlated) with its Ptb Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ptb Ratio has no effect on the direction of Pb Ratio i.e., INmune Bio's Pb Ratio and Ptb Ratio go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Pb Ratio

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most indicators from INmune Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into INmune Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 640.10, whereas Selling General Administrative is forecasted to decline to about 6.8 M.

	2010	2025	2026 (projected)
Interest Income	77.7K	69.9K	62.2K
Net Interest Income	77.7K	69.9K	62.2K

Interest Income Net Interest Income

INmune Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Receivables	Common Stock Total Equity	Other Current Assets	Short Long Term Debt	Short Term Debt	Net Invested Capital	Net Working Capital	Intangible Assets	Retained Earnings Total Equity
Total Assets		0.23	0.68	0.99	0.9	-0.97	-0.66	0.7	0.98	0.98	0.81	0.84	0.76	0.92	0.98	0.27	0.83	0.88	0.89	-0.02	0.63	0.41	0.96	0.94	-0.18	-0.8
Other Current Liab	0.23		0.47	0.25	0.45	-0.11	-0.7	0.66	0.08	0.08	0.62	0.6	0.66	0.16	0.07	0.34	-0.19	-0.05	0.55	0.38	0.85	0.16	0.02	-0.03	-0.56	-0.53
Total Current Liabilities	0.68	0.47		0.61	0.74	-0.6	-0.78	0.85	0.64	0.64	0.78	0.79	0.74	0.84	0.65	0.77	0.63	0.59	0.8	-0.13	0.7	0.85	0.58	0.49	-0.18	-0.88
Total Stockholder Equity	0.99	0.25	0.61		0.88	-0.96	-0.64	0.66	0.96	0.96	0.81	0.83	0.75	0.86	0.95	0.2	0.77	0.85	0.88	0.02	0.63	0.31	0.94	0.93	-0.19	-0.76
Net Tangible Assets	0.9	0.45	0.74	0.88		-0.89	-0.88	0.91	0.88	0.88	0.87	0.97	0.94	0.85	0.87	0.29	0.62	0.73	0.92	-0.12	0.8	0.34	0.85	0.83	-0.48	-0.93
Net Debt	-0.97	-0.11	-0.6	-0.96	-0.89		0.61	-0.65	-0.99	-0.99	-0.72	-0.79	-0.71	-0.89	-0.99	-0.22	-0.83	-0.85	-0.82	0.07	-0.52	-0.33	-0.98	-0.98	0.14	0.75
Retained Earnings	-0.66	-0.7	-0.78	-0.64	-0.88	0.61		-0.98	-0.6	-0.6	-0.9	-0.95	-0.97	-0.67	-0.59	-0.35	-0.33	-0.49	-0.87	0.11	-0.91	-0.36	-0.54	-0.49	0.55	0.95
Accounts Payable	0.7	0.66	0.85	0.66	0.91	-0.65	-0.98		0.65	0.65	0.88	0.96	0.97	0.75	0.65	0.47	0.43	0.54	0.87	-0.16	0.9	0.48	0.61	0.54	-0.59	-0.97
Cash	0.98	0.08	0.64	0.96	0.88	-0.99	-0.6	0.65		1.0	0.71	0.79	0.7	0.93	1.0	0.27	0.88	0.89	0.81	-0.09	0.5	0.4	0.99	0.98	-0.13	-0.76
Cash And Short Term Investments	0.98	0.08	0.64	0.96	0.88	-0.99	-0.6	0.65	1.0		0.71	0.79	0.7	0.93	1.0	0.27	0.88	0.89	0.81	-0.09	0.5	0.4	0.99	0.98	-0.13	-0.76
Common Stock Shares Outstanding	0.81	0.62	0.78	0.81	0.87	-0.72	-0.9	0.88	0.71	0.71		0.92	0.91	0.74	0.7	0.32	0.47	0.6	0.98	-0.03	0.89	0.36	0.64	0.6	-0.34	-0.9
Capital Surpluse	0.84	0.6	0.79	0.83	0.97	-0.79	-0.95	0.96	0.79	0.79	0.92		0.99	0.81	0.78	0.33	0.53	0.68	0.94	-0.07	0.9	0.39	0.75	0.71	-0.55	-0.97
Other Stockholder Equity	0.76	0.66	0.74	0.75	0.94	-0.71	-0.97	0.97	0.7	0.7	0.91	0.99		0.72	0.69	0.28	0.41	0.58	0.9	-0.08	0.92	0.3	0.66	0.62	-0.63	-0.95
Total Liab	0.92	0.16	0.84	0.86	0.85	-0.89	-0.67	0.75	0.93	0.93	0.74	0.81	0.72		0.94	0.48	0.92	0.89	0.82	-0.14	0.55	0.66	0.91	0.87	-0.13	-0.85
Total Current Assets	0.98	0.07	0.65	0.95	0.87	-0.99	-0.59	0.65	1.0	1.0	0.7	0.78	0.69	0.94		0.26	0.9	0.91	0.81	-0.09	0.49	0.42	0.99	0.98	-0.13	-0.76
Common Stock	0.27	0.34	0.77	0.2	0.29	-0.22	-0.35	0.47	0.27	0.27	0.32	0.33	0.28	0.48	0.26		0.39	0.12	0.35	-0.06	0.37	0.89	0.2	0.1	0.06	-0.42
Short Long Term Debt Total	0.83	-0.19	0.63	0.77	0.62	-0.83	-0.33	0.43	0.88	0.88	0.47	0.53	0.41	0.92	0.9	0.39		0.89	0.58	-0.11	0.2	0.62	0.89	0.86	0.15	-0.58
Net Receivables	0.88	-0.05	0.59	0.85	0.73	-0.85	-0.49	0.54	0.89	0.89	0.6	0.68	0.58	0.89	0.91	0.12	0.89		0.68	-0.1	0.36	0.44	0.91	0.9	-0.11	-0.69
Common Stock Total Equity	0.89	0.55	0.8	0.88	0.92	-0.82	-0.87	0.87	0.81	0.81	0.98	0.94	0.9	0.82	0.81	0.35	0.58	0.68		0.01	0.84	0.41	0.75	0.71	-0.29	-0.92
Other Current Assets	-0.02	0.38	-0.13	0.02	-0.12	0.07	0.11	-0.16	-0.09	-0.09	-0.03	-0.07	-0.08	-0.14	-0.09	-0.06	-0.11	-0.1	0.01		0.03	-0.1	-0.1	-0.09	0.09	0.14
Short Long Term Debt	0.63	0.85	0.7	0.63	0.8	-0.52	-0.91	0.9	0.5	0.5	0.89	0.9	0.92	0.55	0.49	0.37	0.2	0.36	0.84	0.03		0.29	0.45	0.39	-0.62	-0.83
Short Term Debt	0.41	0.16	0.85	0.31	0.34	-0.33	-0.36	0.48	0.4	0.4	0.36	0.39	0.3	0.66	0.42	0.89	0.62	0.44	0.41	-0.1	0.29		0.36	0.27	0.13	-0.52
Net Invested Capital	0.96	0.02	0.58	0.94	0.85	-0.98	-0.54	0.61	0.99	0.99	0.64	0.75	0.66	0.91	0.99	0.2	0.89	0.91	0.75	-0.1	0.45	0.36		0.99	-0.18	-0.72
Net Working Capital	0.94	-0.03	0.49	0.93	0.83	-0.98	-0.49	0.54	0.98	0.98	0.6	0.71	0.62	0.87	0.98	0.1	0.86	0.9	0.71	-0.09	0.39	0.27	0.99		-0.15	-0.66
Intangible Assets	-0.18	-0.56	-0.18	-0.19	-0.48	0.14	0.55	-0.59	-0.13	-0.13	-0.34	-0.55	-0.63	-0.13	-0.13	0.06	0.15	-0.11	-0.29	0.09	-0.62	0.13	-0.18	-0.15		0.42
Retained Earnings Total Equity	-0.8	-0.53	-0.88	-0.76	-0.93	0.75	0.95	-0.97	-0.76	-0.76	-0.9	-0.97	-0.95	-0.85	-0.76	-0.42	-0.58	-0.69	-0.92	0.14	-0.83	-0.52	-0.72	-0.66	0.42

Click cells to compare fundamentals

INmune Bio Account Relationship Matchups

INmune Bio fundamental ratios Accounts

	2021	2022	2023	2024	2025	2026 (projected)
Total Assets	99.9M	81.8M	57.0M	39.6M	45.5M	41.8M
Other Current Liab	(62K)	9K	524K	517K	594.6K	624.3K
Total Current Liabilities	4.4M	10.9M	18.5M	7.2M	8.3M	5.0M
Total Stockholder Equity	80.2M	60.1M	38.1M	32.1M	36.9M	33.8M
Net Tangible Assets	7.1M	22.2M	63.7M	43.6M	50.1M	52.6M
Net Debt	(59.6M)	(36.8M)	(25.4M)	(20.5M)	(18.5M)	(19.4M)
Retained Earnings	(63.7M)	(91.0M)	(121.0M)	(163.1M)	(146.8M)	(139.5M)
Accounts Payable	3.8M	5.2M	7.9M	6.6M	7.5M	7.9M
Cash	74.8M	52.2M	35.8M	20.9M	24.1M	23.6M
Cash And Short Term Investments	74.8M	52.2M	35.8M	20.9M	24.1M	23.6M
Common Stock Shares Outstanding	16.1M	17.9M	18.0M	19.9M	22.9M	13.9M
Liabilities And Stockholders Equity	99.9M	81.8M	57.0M	39.6M	45.5M	41.8M
Capital Surpluse	44.8M	72.1M	143.9M	151.8M	174.6M	183.3M
Other Stockholder Equity	143.9M	151.8M	159.1M	195.8M	225.1M	236.4M
Total Liab	19.7M	21.7M	18.9M	7.5M	8.6M	7.9M
Total Current Assets	82.6M	64.7M	39.9M	22.7M	26.1M	26.9M
Short Long Term Debt Total	15.2M	15.3M	10.4M	384K	441.6K	419.5K
Non Current Assets Total	17.3M	17.1M	17.1M	16.9M	19.4M	16.5M
Net Receivables	5.5M	8.5M	2.4M	1.4M	1.6M	2.6M
Non Current Liabilities Total	15.4M	10.8M	397K	244K	280.6K	266.6K
Other Current Assets	7.8M	4.0M	1.7M	331K	297.9K	283.0K
Accumulated Other Comprehensive Income	1K	(699K)	(799K)	(575K)	(517.5K)	(491.6K)
Short Term Debt	144K	5.1M	10.0M	140K	161K	153.0K
Net Invested Capital	94.7M	74.8M	48.1M	32.1M	36.9M	47.7M
Net Working Capital	78.2M	53.8M	21.5M	15.4M	17.8M	27.5M
Retained Earnings Total Equity	(21.3M)	(33.4M)	(63.7M)	(91.0M)	(81.9M)	(77.8M)
Property Plant And Equipment Net	726K	507K	414K	307K	353.1K	422.0K
Current Deferred Revenue	190.6K	474K	616K	489K	562.4K	323.7K
Capital Lease Obligations	776K	613K	516K	384K	441.6K	479.9K
Property Plant And Equipment Gross	726K	507K	414K	307K	353.1K	422.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

JBL	Jabil Circuit
MRK	Merck Company
AMGN	Amgen Inc

When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:

How To Invest In INmune

Details

Is INmune Stock a good investment?

Details

What is INmune Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in INmune Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry.

For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.

You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Revenue Per Share

0.002

Quarterly Revenue Growth

2.571

Return On Assets

(0.51)

Return On Equity

(1.56)

The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2026 Macroaxis LLC

INmune Pb Ratio vs Ptb Ratio Analysis

Pb Ratio vs Ptb Ratio

Pb Ratio vs Ptb Ratio Correlation Analysis

Correlation Coefficient

Pb Ratio

Ptb Ratio

INmune Bio fundamental ratios Correlations

INmune Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

INmune Bio fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Cash
Net Invested Capital	+ 0.99	Cash And Short Term Investments

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Accounts Payable	- 0.98	Retained Earnings
Net Working Capital	- 0.98	Net Debt
Net Invested Capital	- 0.98	Net Debt